Biochemical Validation of Patient-Reported Symptom Onset Time in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention  by Mahmoud, Karim D. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 1 2 . 2 4 2Biochemical Validation of Patient-
Reported Symptom Onset Time in
Patients With ST-Segment Elevation
Myocardial Infarction Undergoing Primary
Percutaneous Coronary Intervention
Karim D. Mahmoud, MD, PHD,*y Hans L. Hillege, MD, PHD,y Allan S. Jaffe, MD,*z Ryan J. Lennon, MS,x
David R. Holmes JR, MD*ABSTRACTFro
Un
an
Ro
Tri
thi
MaOBJECTIVES This study evaluated a biochemical validation of patient-reported symptom onset time in patients with
ST-segment elevation myocardial infarction (STEMI).
BACKGROUND Symptom onset time is an important metric but has never been formally validated.
METHODS The Mayo Clinic Percutaneous Coronary Intervention (PCI) Registry was interrogated to obtain baseline,
procedural, and outcome data on 607 STEMI patients undergoing primary PCI. Biochemical onset time was determined by
backward extrapolation of serial increasing cardiac troponin T (cTnT) measurements.
RESULTS The median patient-reported onset time was 12 min later than the calculated time of ﬁrst cTnT increase and
was therefore estimated to be 4.2 h later than the biochemical onset time (interquartile range: 1.9 to 11.1 h; p < 0.001),
assuming a 4-h interval between coronary occlusion and ﬁrst cTnT increase. Conventional ischemic time showed no
association with infarct size (correlation with peak cTnT: r ¼ 0.023; p ¼ 0.61) or 1-year mortality (hazard ratio: 0.97
per doubling; 95% conﬁdence interval: 0.68 to 1.40; p ¼ 0.88). However, after recalculation of ischemic time with
biochemical onset time, signiﬁcant associations with infarct size (r ¼ 0.14; p ¼ 0.001) and 1-year mortality (hazard ratio:
1.70 per doubling; 95% conﬁdence interval: 1.20 to 2.40; p ¼ 0.003) were found. When underestimation of ischemic
time by patient-reported onset time increased, so did the risk of mortality.
CONCLUSIONS Although our point estimate should be interpreted with caution, our study indicates that the actual
onset of STEMI is likely to be earlier than the patient-reported onset time. Recalculation of ischemic time with
biochemical onset time greatly enhanced its prognostic value. Underestimation of ischemic time by patient-reported
onset time occurred more often in high-risk patients. (J Am Coll Cardiol Intv 2015;8:778–87) © 2015 by the American
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AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
cTnI = cardiac troponin I
cTnT = cardiac troponin T
IQR = interquartile range
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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779reperfusion strategy in patients with STEMI. Observa-
tional studies and a recent clinical trial have sug-
gested that a pharmacoinvasive approach consisting
of (pre-hospital) ﬁbrinolysis with timely angiography
may result in a superior outcome compared with pri-
mary percutaneous coronary intervention (PCI) in
STEMI patients presenting within 3 h of symptom
onset in whom delays to primary PCI are expected
to be substantial (5–7). Similarly, current guidelines
do not recommend routine reperfusion therapy in
stable STEMI patients without clinical and electrocar-
diographic evidence of ongoing ischemia when time
from symptom onset to presentation is more than
12 to 24 h (1).SEE PAGE 788Despite this growing importance of symptom onset
time, previous reports have pointed out that reported
symptom onset time is subjective information and is
likely to be an inaccurate measure of true time of
onset of myocardial infarction (8,9). Some subgroups
of patients are known for their often atypical symp-
toms such as women, those with diabetes, and elderly
patients (10,11), which may further jeopardize the
accuracy of reported symptom onset time. Further-
more, patients may report an episode of angina before
coronary artery occlusion as the time of symptom
onset. To the best of our knowledge, symptom onset
time in STEMI has never been formally validated. In
the present study, we validated patient-reported
symptom onset time with biochemical onset time,
which was estimated using cardiac troponin T (cTnT)
concentrations. We determined the accuracy of
patient-reported symptom onset time in the overall
population and in relevant subgroups. Furthermore,
we assessed the prognostic value of ischemic time
using reported symptom onset time versus ischemic
time using biochemical onset time.
METHODS
STUDY DESIGN. The Mayo Clinic PCI Registry was
interrogated to obtain baseline, procedural, and
outcome data on consecutive patients with STEMI
undergoing primary PCI between 2004 and 2012 at
the Mayo Clinic, Rochester, Minnesota. For this reg-
istry, data are prospectively collected by experienced
interventional cardiology data technicians. After
discharge, follow-up data are collected by a periodic
standardized telephone survey with the patient. All
adverse events are conﬁrmed by reviewing the med-
ical records of the patients followed at our institution
and by contacting the patients’ physicians and
reviewing the hospital records of patients treatedelsewhere. The database supervisor ran-
domly audits 10% of the records for quality
control purposes. STEMI was deﬁned as
symptoms suggestive of myocardial ischemia
and an electrocardiogram with either new or
presumed new ST-segment elevation or left
bundle branch block. ST-segment elevation
was deﬁned as an increase of 1 mm or more in
ST segments in 2 or more limb leads or an
increase of 2 mm or more in 2 or more
contiguous precordial leads. Patients were
included if they had at least 2 increasing cTnT
measurements within 24 h of patient-
reported symptom onset time. Furthermore, the
peak cTnT concentration had to be at least 5 times
greater than the minimal value to allow for an accu-
rate calculation of biochemical onset time. Exclusion
criteria were moderate to severe renal disease
(deﬁned as creatinine >265 mmol/l [>3.0 mg/dl] or on
dialysis or previous kidney transplantation), a previ-
ous PCI procedure within 7 days of the primary PCI
procedure, unreported symptom onset time, and pa-
tient refusal to have their medical records reviewed
for research. The study protocol was approved by the
institutional review board.
METHODS OF MEASUREMENT. All patient baseline
data were documented on admission. Hypertension
was deﬁned as a documented history or treatment
with medication. Current smoking was deﬁned as
having smoked cigarettes within the past 6 months.
Diabetes was deﬁned as a documented diagnosis
requiring treatment with medication or diet. Hyper-
cholesterolemia was deﬁned as total cholesterol
>6.2 mmol/l (>240 mg/dl) or on drug therapy. Posi-
tive family history was deﬁned as a family history of
premature coronary heart disease (55 years of age or
younger). Pre-procedural shock was deﬁned as a
systolic blood pressure <95 mm Hg or <110 mm Hg on
inotropic support. Multivessel disease was deﬁned as
a stenotic lesion of $50% in a vessel other than the
culprit coronary artery. Symptom onset time was
deﬁned as patient-reported date and time of onset of
symptoms. In case of atypical or stuttering symp-
toms, the most likely time of onset of myocardial
infarction was determined by the attending physician
in discussion with the patient. To calculate bio-
chemical onset time, serial blood levels of cTnT
were used. cTnT levels are routinely measured in all
STEMI patients following a standardized protocol
on admission and at 3 and 6 h on an electro-
chemiluminescence immunoassay (Elecsys, Roche
Diagnostics, Indianapolis, Indiana) with a coefﬁcient
of variation <10% at 0.035 ng/ml, a lower limit of
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780detection of 0.01 ng/ml, and a 99th percentile refer-
ence limit <0.01 ng/ml in accordance with current
guidelines for the diagnosis of myocardial infarction
(12). Treatment time was the date and time docu-
mented in the catheterization procedure note as the
time of ﬁrst device used to open the coronary artery
including a balloon, stent, or thrombectomy device.
Conventional ischemic time was derived from re-
ported symptom onset time and treatment time,
whereas biochemical ischemic time was derived from
biochemical onset time and treatment time. Throm-
bolysis In Myocardial Infarction (TIMI) ﬂow grade was
scored by the operator during the PCI procedure.
Outcome measures included peak cTnT, which is a
validated measure of infarct size (13,14) and all-cause
mortality during hospitalization and at 1-year follow-
up. One-year follow-up was completed in 93% of the
included patients.
STATISTICAL ANALYSIS. Continuous variables were
summarized as mean  SD or median and interquartile
range (IQR). Discrete variables were presented as
numbers and percentages. Bivariate associations
were assessed with Spearman’s correlation, groupnation of Biochemical Onset Time
nsformation of both axes, a regression line was ﬁtted to the increasing
TnT) values in each patient. Extrapolation of this line allowed esti-
f ﬁrst cTnT increase. Finally, a constant factor (C) was added to
ween coronary occlusion and ﬁrst cTnT elevation.differences were tested with the Mann-Whitney U
test, and differences between paired observations
were tested with the Wilcoxon signed rank test. To
calculate the biochemical onset time, we adopted an
approach as reported in a historical study that vali-
dated the circadian variation in acute myocardial
infarction with creatine kinase myocardial band levels
(15). Assuming a monoexponential increase in cTnT in
STEMI patients, a regression line was ﬁtted to the
increasing cTnT levels in each patient after logarith-
mic transformation of both time and cTnT. By using a
Tobit model, cTnT levels below 0.01 ng/ml could
be considered as censored data in the modeling pro-
cess (16). Backward extrapolation of the regression
function allowed us to estimate the time of initial
elevation of cTnT (deﬁned as cTnT ¼ 0.01 ng/ml).
We then subtracted a predeﬁned constant term from
this time point, to account for the time between
coronary occlusion and initial elevation of cTnT
(Figure 1). On the basis of on previous studies, we
chose a constant term of 4 h for all patients (17,18).
Reported symptom onset time was compared with
biochemical onset time in the overall population
and in pre-speciﬁed subgroups on the basis of age
(65 years of age and older), sex, body mass index (BMI)
(above the median), hypertension, diabetes, hyper-
cholesterolemia, current smoking, positive family
history, previous myocardial infarction, previous PCI,
previous coronary artery bypass grafting, reported
symptom onset at night (midnight through 05:59),
congestive heart failure on admission, pre-procedural
shock, multivessel disease, and pre-procedural TIMI
ﬂow grade (>0). After logarithmic transformation
of ischemic time, we used univariable Cox propor-
tional hazards models to assess the association
between ischemic time and 1-year mortality. For this
analysis, ischemic time was calculated both with
reported symptom onset time and biochemical
onset time. In sensitivity analyses, the study results
were recalculated with the following modiﬁcations:
1) selection of a constant factor of 2 h between coro-
nary occlusion and initial elevation of cTnT; 2) exclu-
sion of patients with post-procedural TIMI ﬂow
grade <3; and 3) exclusion of patients with only 2 cTnT
measurements when 1 of these measurements was
<0.01 ng/ml. All statistical analyses were performed
using SAS version 9.3 (SAS Institute Inc., Cary,
North Carolina), and statistical signiﬁcance was set at
p < 0.05 (2-tailed).
RESULTS
There were 1,809 eligible primary PCI cases in pa-
tients with STEMI between January 1, 2004 and
FIGURE 2 Study Design and Participants
Flowchart of patient selection for this study. cTnT ¼ cardiac troponin T; PCI ¼ percuta-
neous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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781December 31, 2012. Of these, we excluded 1,174 pa-
tients in whom cTnT measurements were not suitable
for biochemical onset time calculation, 15 patients
who had had a previous PCI procedure within the past
7 days, and 13 patients with moderate to severe renal
failure (Figure 2). Thus, 607 STEMI patients were
included in the present analysis. Baseline and pro-
cedural characteristics of the included and excluded
patients are listed in Table 1. In the included patients,
the mean age was 62.6 years, 23% were female, and
the mean BMI was 28.9 kg/m2. The rate of current
smokers was 33%, diabetes was present in 17% of
patients, and 19% of patients had a history of PCI. On
coronary angiography, TIMI ﬂow grade 0 was found
in 62% of patients and multivessel disease in 65%.
The average number of cTnT measurements was
3.2, of which an average of 2.7 measurements was
increasing.
Patients excluded from this study were more likely
to be female, to have higher rates of hypertension and
longer ischemic time, but were less likely to have a
positive family history (Table 1). Pre-procedural TIMI
ﬂow grade 0 was less often found in excluded pa-
tients. Treatment was similar in excluded patients,
except for less right coronary artery interventions at
the expense of more left anterior descending artery
interventions. Mortality was higher in excluded
patients.
REPORTED ONSET TIME VERSUS BIOCHEMICAL
ONSET TIME. Overall, the median reported symptom
onset time was 12 min later than the estimated
time of ﬁrst cTnT increase. As we assumed a time
interval of 4 h from coronary occlusion to ﬁrst
cTnT increase, biochemical onset time tended to be
earlier than reported symptom onset time, with a
median difference of 4.2 h (IQR: 11.1 to 1.9 h;
p < 0.001) (Figure 3). Subgroup differences are
shown in Figure 4. Compared with the reference
population, biochemical onset time was especially
earlier than reported symptom onset time in pa-
tients aged 65 years of age and older (median:
4.8 h; IQR: 13.4 to 2.2 h; p ¼ 0.001), in patients
with a BMI <28 kg/m2 (median: 4.7 h; IQR: 12.9
to 2.1 h; p ¼ 0.006), in patients without a history of
PCI (median: 4.3; IQR: 11.1 to 2.2 h; p ¼ 0.038),
and in patients with a pre-procedural TIMI ﬂow
grade >0 (median: 5.5; IQR: 15.3 to 2.0 h;
p ¼ 0.001). No differences were seen in subgroups
on the basis of sex, diabetes, or reported symptom
onset at night.
ASSOCIATION WITH ISCHEMIC TIME. When calcu-
lated using reported symptom onset time, median
conventional ischemic time was 3.7 h (IQR: 2.4 to6.1 h). Recalculation by using biochemical onset time
resulted in a median biochemical ischemic time of
8.6 h (IQR: 5.1 to 17.4 h). Biochemical ischemic time
tended to be longer than conventional ischemic time,
although the 2 measures showed good agreement in
patients with ischemic times >12 h (overall correla-
tion, r ¼ 0.39; p < 0.001) (Figure 5).
ASSOCIATION WITH OUTCOME. To verify the inter-
nal validity of biochemical onset time and compare
the prognostic value of conventional ischemic time
and biochemical ischemic time, their association with
biochemical infarct size and mortality was assessed.
Overall, the median peak cTnT was 3.7 ng/ml (IQR: 1.7
to 7.2 ng/ml). Although conventional ischemic time
did not correlate with peak cTnT (r ¼ 0.023; p ¼ 0.61)
(Figure 6A), there was a signiﬁcant positive
TABLE 1 Baseline, Procedural, and Outcome Data
Included Patients
(n ¼ 607)
Excluded Patients
(n ¼ 1,202) p Value
Baseline
Age, yrs 62.6  13.4 64.0  13.7 0.036
Female 140 (23) 355 (30) 0.004
Body mass index, kg/m2 28.9  5.3 29.1  6.1 0.44
Hypertension 347 (62) 791 (69) 0.004
Diabetes mellitus 101 (17) 210 (18) 0.68
Hypercholesterolemia 372 (69) 755 (68) 0.61
Smoking status 0.52
Current 195 (33) 412 (35)
Former 199 (34) 391 (33)
Never 197 (33) 385 (32)
Family history <0.001
Positive 154 (25) 253 (21)
Negative 260 (43) 673 (56)
Unknown 193 (32) 276 (23)
Previous myocardial infarction 96 (16) 206 (17) 0.47
Previous PCI 115 (19) 268 (22) 0.10
Previous CABG 32 (5) 79 (7) 0.29
Congestive heart failure 0.14
Current 46 (8) 110 (9)
Previous 8 (1) 24 (2)
Never 543 (91) 1,044 (89)
Pre-procedural shock 74 (12) 129 (11) 0.34
Conventional ischemic time, h 3.7 (2.4–6.1) 4.8 (2.7–10.1) <0.001
Procedural
Multivessel disease 392 (65) 779 (66) 0.67
Pre-procedural TIMI ﬂow grade 0 331 (62) 562 (52) <0.001
Target coronary artery*
Left anterior descending 208 (34) 522 (44) <0.001
Right 320 (53) 486 (41) <0.001
Circumﬂex 87 (14) 206 (17) 0.12
Left main 0 (0) 21 (2) 0.001
Graft 16 (3) 36 (3) 0.66
No. of segments treated 1.3  0.6 1.4  0.6 0.71
No. of stents placed 1.2  0.7 1.2  0.8 0.59
Use of drug-eluting stents 424 (70) 794 (66) 0.13
Periprocedural GP IIb/IIIa use 511 (84) 983 (82) 0.20
Outcome
Post-procedural TIMI ﬂow grade 3 531 (93) 1,050 (91) 0.26
Peak cardiac troponin T, ng/ml 3.7 (1.7–7.2) 1.3 (0.1–4.4) <0.001
Death
In-hospital 11 (1.8) 61 (5.1) <0.001
1-year 34 (5.7) 119 (10) <0.001
Values are mean  SD, n (%), or median (interquartile range). *Sum is >100% because of mul-
tivessel procedures.
CABG ¼ coronary artery bypass grafting; GP ¼ glycoprotein; PCI ¼ percutaneous coronary
intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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782correlation between biochemical ischemic time and
peak cTnT (r ¼ 0.14; p ¼ 0.001) (Figure 6B).
At follow-up, in-hospital mortality was 1.8% and
1-year mortality was 5.7% (Table 1). No association
was found between conventional ischemic time and
1-year mortality (hazard ratio: 0.97 per doubling;95% conﬁdence interval: 0.68 to 1.40; p ¼ 0.88).
In contrast, longer biochemical ischemic time was
clearly predictive of 1-year mortality (hazard ratio:
1.70 per doubling; 95% conﬁdence interval: 1.20 to
2.40; p ¼ 0.003). To gain further insight into this
pattern, we also assessed the predictive value of
the ratio of biochemical ischemic time over conven-
tional ischemic time. An increase in this ratio was
also predictive of 1-year mortality (hazard ratio: 1.60
per doubling; 95% conﬁdence interval: 1.18 to 2.18;
p ¼ 0.003), indicating that shorter conventional
ischemic time relative to biochemical ischemic time
was more common in patients at higher risk of 1-year
mortality.
SENSITIVITY ANALYSES. Full results of the sensi-
tivity analyses are listed in the Online Appendix.
Adjustment of the constant factor between coronary
occlusion and initial increase in cTnT to 2 h resulted in
a median difference between biochemical onset time
and reported symptom onset time of 2.2 h (IQR:
9.1 to 0.1 h; p < 0.001), but did not affect any of
the other analyses substantially. Results were also
similar after exclusion of patients with post-
procedural TIMI ﬂow grade <3 (n ¼ 76), thus arguing
against a signiﬁcant bias in the modeling process due
to cTnT washout after reperfusion. Finally, we recal-
culated our results after exclusion of patients with
only 2 cTnT measurements when the ﬁrst measure-
ment was <0.01 ng/ml (n ¼ 85). This represented the
group of patients with the most scarce data to model
cTnT, and the Tobit model showed a slight bias
toward later biochemical onset time in these patients.
In the remaining patients, the difference between
biochemical onset time and reported symptom onset
time was greater and the correlation between
biochemical ischemic time and peak cTnT was weaker
(r ¼ 0.08; p ¼ 0.081), although performance was still
better than conventional ischemic time. Results were
otherwise similar.
DISCUSSION
To the best of our knowledge, we are the ﬁrst to
validate symptom onset time in patients with STEMI.
Patient-reported symptom onset time was compared
with biochemical onset time, which was derived from
serial cTnT measurements. We found that reported
symptom onset time tended to be later than bio-
chemical onset time and that this phenomenon was
even more pronounced in elderly patients, in patients
with a BMI <28 kg/m2, in patients without a history
of PCI, and in patients with residual ﬂow in the
culprit artery on coronary angiography. Conventional
FIGURE 3 Distribution of the Difference Between Biochemical Onset Time and
Reported Symptom Onset Time
Median biochemical onset time was 4.2 h earlier than reported onset time (interquartile
range: 1.9 to 11.1 h; p < 0.001). The blue line indicates the estimated density function
using a kernel estimator.
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783ischemic time—reported symptom onset to treatment
time—did not correlate with peak cTnT and mortality.
Conversely, biochemical ischemic time—biochemical
onset to treatment time—was associated with peak
cTnT and mortality. An increase in the ratio of
biochemical ischemic time over conventional
ischemic time was also associated with mortality,
indicating that larger differences between these
measures were more frequent in patients at higher
risk of death.
Although our ﬁndings are novel and compelling, a
thorough understanding of the methodology applied
to determine biochemical onset time is crucial to the
interpretation of our results. As shown in Figure 1,
backward extrapolation of serial increasing cTnT
measurements was used to estimate the time of
initial cTnT increase. From this time point, 4 h were
subtracted in all patients to account for the time
between coronary occlusion and ﬁrst cTnT increase.
This constant term was predeﬁned and was based on
the need for coronary perfusion for biomarkers to
reach the peripheral circulation as well as the scarce
data available from previous studies investigating
this relationship (17,18). In 197 patients presenting
with chest pain, Eggers et al. (17) demonstrated that
86% of patients ultimately classiﬁed as non–STEMI
had increased cardiac troponin I (cTnI) levels within
4 h of symptom onset. In another study, cTnI mea-
surements were performed on admission in patients
presenting with chest pain. In this study, it was
demonstrated that a second cTnI measurement per-
formed at least 3 h after symptom onset identiﬁed
78% of patients who would have an increased cTnI
value 6 h after admission (18). However, these
studies relied on reported symptom onset time and
are prone to the very bias that we tried to assess in
this study. Furthermore, they were predominantly
conducted in non-NSTEMI patients in whom the
infarct-related artery is usually not fully occluded.
Patient-reported symptom onset time is probably
later than the thrombotic coronary event in these
patients, as was the case in our study in STEMI pa-
tients with residual ﬂow in the culprit coronary ar-
tery. Thus, the choice of the constant remains
arbitrary to some extent because the true time of
coronary occlusion cannot be known. Accordingly,
the point estimate of the median difference between
biochemical onset time and reported symptom onset
time found in our study (4.2 h) should be inter-
preted with caution. Still, regardless of the constant
factor, the median reported symptom onset time in
our study roughly coincided with the estimated time
of ﬁrst cTnT increase, thereby representing clear
evidence that reported symptom onset time is laterthan the actual time of onset of STEMI. Moreover, a
sensitivity analysis demonstrated that modiﬁcation
of the constant factor did not materially change the
results of any of the other analyses reported in this
study.
In a sensitivity analysis, the association between
biochemical ischemic time and peak cTnT was no
longer signiﬁcant after exclusion of patients with 1
undetectable and 1 increased cTnT value. Although
this could be related to the modeling of cTnT, other
explanations are also plausible. Clearly, a sample size
reduction limits the statistical power to detect any
association. More importantly, patients with initially
undetectable cTnT values are likely to be early pre-
senters and generally have a favorable outcome (19).
Selective exclusion of these patients may com-
promise the association between ischemic time and
outcome.
We found greater deviation between reported
symptom onset time and biochemical onset time in
elderly patients. This ﬁnding is consistent with ﬁnd-
ings of previous studies, showing that elderly pa-
tients with acute myocardial infarction more often
present with atypical symptoms such as dyspnea and
faintness (10). In addition, recollection of time of
onset may be less accurate in elderly patients.
FIGURE 4 Subgroup Differences in Biochemical Onset Time Relative to Reported Symptom Onset Time
Biochemical onset time was particularly earlier in patients $65 years of age and patients with a preprocedural TIMI ﬂow >0. CABG ¼ coronary
artery bypass grafting; CHF ¼ congestive heart failure; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
TIMI ¼ Thrombolysis In Myocardial Infarction.
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FIGURE 5 Correlation Between Conventional Ischemic Time
and Biochemical Ischemic Time
The line indicates a spline smoother to help visualize the trend
(r ¼ 0.39; p < 0.001).
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785Reported symptom onset time also tended to be later
than biochemical onset time in patients with TIMI
ﬂow grade >0 on coronary angiography. This group of
patients may experience a “stuttering myocardial
infarction,” in which transient episodes of (sub)total
coronary occlusion are accompanied by waxing and
waning of ischemic symptoms, thereby complicating
determination of actual time of onset of symptoms
(20). Furthermore, reported symptom onset time was
later than could be expected from biochemical onset
time in patients with a lower BMI and patients
without a history of PCI procedures. These patients
have not been identiﬁed as subgroups with an atyp-
ical symptom presentation in previous studies. A
possible explanation is that these patients were not
made aware of the symptoms associated with
myocardial infarction by their physicians because of
their lower risk of cardiovascular events. Hence, they
may not have attributed the initial symptoms as being
cardiac. In this context, however, it should also be
stressed that atypical symptoms such as dyspnea and
nausea, although more difﬁcult to attribute as car-
diac, do not necessarily preclude adequate recollec-
tion of onset time. This may explain why we did not
ﬁnd differences in other subgroups known for their
atypical symptom presentation such as women and
those with diabetes (10,11).
The pathophysiological importance of total
ischemic time in patients with STEMI is wellFIGURE 6 Correlation Between Ischemic Time and Biochemical Infar
(A) Correlation between conventional ischemic time and infarct size (r ¼
(r ¼ 0.14; p ¼ 0.001). The line indicates a spline smoother to help visurecognized (21). However, some previous studies in
patients undergoing primary PCI failed to show as-
sociations between ischemic time and infarct size,
myocardial salvage index, left ventricular ejection
fraction, and mortality (8,9). Remarkably, associa-
tions with these outcome measures could bect Size as Assessed by Peak Cardiac Troponin T
0.023; p ¼ 0.61). (B) Correlation between biochemical ischemic time and infarct size
alize the trend.
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786demonstrated when ischemic time was replaced with
a more objective measure such as system delay. Our
ﬁndings help to explain these observations by
showing that the prognostic value of ischemic time
was greatly enhanced when it was systematically
determined in a manner that was less prone to bias
than the use of reported symptom onset time.
Importantly, reported symptom onset time tended to
underestimate ischemic time to a greater extent in
patients at higher risk of mortality, thereby further
obscuring the association between ischemic time and
clinical outcome.
The retrospective methodology that we applied
to determine biochemical onset time limits its
applicability for reperfusion strategy selection in
clinical practice. Nonetheless, the use of biochem-
ical onset time in future studies may enhance our
knowledge about the interaction between time from
symptom onset, reperfusion strategy selection, and
outcome in STEMI patients. In addition, clinicians
should be aware that reported symptom onset
time is typically later than the actual time of onset
of STEMI, especially in the subgroups identiﬁed in
this study and in high-risk patients. Our results
suggest that other readily available measures that
reﬂect time from onset of STEMI should also be
considered when selecting a reperfusion strategy,
such as the presence of Q waves on the baseline
electrocardiogram (22,23). However, we do not
argue against the current guideline recommenda-
tions to consider conservative management in sta-
ble STEMI patients without evidence of ongoing
ischemia when the time from symptom onset to
presentation is more than 12 to 24 h because con-
ventional ischemic time correlated well with
biochemical ischemic time in patients with ischemic
time beyond 12 h (1).
STUDY LIMITATIONS. As stated earlier, the most
important limitation of our study is the fact that true
time of onset of STEMI cannot be known and that
there is neither a gold standard for onset time nor
one for ischemic time. Nonetheless, biochemical
ischemic time greatly outperformed conventional
ischemic time as a prognostic marker, thus showing
good internal validity. Second, biochemical onset
time could only be reliably calculated in patients
with sufﬁcient and increasing cTnT measurements.
Exclusion of a substantial number of patients with
inadequate cTnT measurements inadvertently
resulted in selection of a lower risk population, as is
reﬂected by the lower mortality rate in included
patients. Third, the lack of routine cTnT samplingbeyond 6 h after admission may explain the rela-
tively low peak cTnT values seen in our study.
However, it did allow us to have consistent
timing for that evaluation, which is a strength. In
addition, studies have suggested that any cTnT
measurement beyond the value on admission shows
a fair correlation with single-photon emission
computed tomography–determined infarct size (14).
Fourth, it is conceivable that a minor plaque
disruption occurs in many patients before the total
occlusion occurs, which may have caused cTnT
release. If one is attempting to measure the onset
of total occlusion, this may be a limitation, but
from the point of view of pathobiology, it might
indeed be a better estimate of onset. We corrected
for the presence of persistent increased values in
patients with renal failure by excluding those pa-
tients, but some of the included patients may still
have had persistently increased cTnT levels due to
other conditions such as left ventricular hypertro-
phy, heart failure, and diabetes, which could also
introduce a bias toward an earlier biochemical onset
time (24).CONCLUSIONS
Our study provides evidence that patient-reported
symptom onset time is later than the actual time
of onset of STEMI in patients undergoing primary
PCI. This phenomenon is especially pronounced in
elderly patients, in patients with a lower BMI, in
patients without a history of PCI, and in patients
with residual ﬂow in the culprit artery on coronary
angiography. Unlike conventional ischemic time,
biochemically determined ischemic time correlated
well with peak cTnT and mortality. Compared with
biochemical onset time, reported symptom onset
time tended to underestimate ischemic time
more in patients at higher risk of 1-year mortality.
Our study shows that minimizing ischemic time
should remain a key goal in STEMI care. Future
studies are required to corroborate our ﬁndings
and assess the association between biochemically
determined ischemic time, preferably with pro-
spectively collected cTnT samples, and infarct size
measured by imaging modalities such as magnetic
resonance imaging.
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PERSPECTIVES
WHAT IS KNOWN? Ischemic time is an important
metric in ST-segment elevation myocardial infarction
care. However, it relies on patient-reported symptom
onset time, which has an uncertain validity.
WHAT IS NEW? Our study provides evidence that
patient-reported symptom onset time is typically later
than the actual onset of the thrombotic coronary event,
especially in speciﬁc subgroups such as elderly patients.
WHAT IS NEXT? Further prospective validation of our
ﬁndings is warranted. In the meantime, clinicians should
be aware of this phenomenon and also take into account
other factors that reﬂect ischemic time, such as Q waves
on the baseline electrocardiogram.
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